key: cord-0723763-rdhpv1wo
authors: Wu, Alan H B; Nguyen, Eric D; Ong, Chui Mei; Yun, Cassandra; Lynch, Kara L
title: Rate of Serum SARS-CoV-2 Antibody Decline for two mRNA Vaccines
date: 2021-10-14
journal: J Appl Lab Med
DOI: 10.1093/jalm/jfab137
sha: 0ff11174fdcb7082beca92f36d244b4f7fd33f2b
doc_id: 723763
cord_uid: rdhpv1wo

nan

showed similar antibody responses between the vaccines (1) there are no data extending beyond 6 months. The long-term antibody response to vaccines may be useful to assess long-term efficacy and the timing of a potential booster injection in adults.

We recruited 189 healthcare workers at ZSFG Hospital who were vaccinated in December 2020 or January 2021 (n=150 Pfizer-BioNTech, n=39 Moderna). We recorded the 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 therefore the FDA has recommended against routine serological testing after vaccination (5).

Standardization of serological assays to demonstrate linearity provide quantitative results in a common unit of measurement and is a necessary step in determining an antibody concentration that infers immunity. Many commercially available methods have small analytical measurement ranges limiting comparison of results between methods. Recently there have been efforts to standardize assay results to a common unit (BAU/mL). The Pylon assay showed correlation of RFU vs BAU/ml using WHO standards however, significant biases still exist due to differences in the assay targets and design (7). A vaccinated individual is likely to have protection through 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47 

Clinical evaluation of the Abbott Alinity SARS-CoV-2 spike-specific quantitative IgG and IgM assays among infected, recovered, and vaccinated groups

Magnitude and kinetics of anti-SARS-CoV-2 antibody responses and their relationship to disease severity

Assessment of SARS-C0V-2 reinfection 1 year after primary infection in a population in Lombardy, Italy

Covid-19 Breakthrough Infections in Vaccinated Health Care Workers

Antibody testing is not currently recommended to assess immunity after COVID-19 vaccination: FDA safety communication

Quantitative SARS-CoV-2 Spike Antibody Response in COVID-19 Patients Using Three Fully Automated Immunoassays and a Surrogate Virus Neutralization Test